Australia - English - Department of Health (Therapeutic Goods Administration)

guerbet australia pty ltd - ioversol, quantity: 678 mg/ml (equivalent: iodine, qty 320 mg/ml) - injection, solution - excipient ingredients: trometamol; sodium calcium edetate; water for injections; trometamol hydrochloride; sodium hydroxide - this product accepted for registration as 'currently supplied' at the time of commencement of the act. indications approved as specified in the letter of 19 april 1993 from dr h. arora are as follows: optiray is indicated in adults for angiography throughout the cardiovascular system by conventional or digital subtraction techniques. these include cerebral, coronary, peripheral, visceral and renal arteriography, aortography, left ventriculography and venography. optiray may be used in intravenous excretory urography. optiray 320 is indicated in children (excluding neonates) for angiography, contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography.

Australia - English - Department of Health (Therapeutic Goods Administration)

guerbet australia pty ltd - ioversol, quantity: 678 mg/ml (equivalent: iodine, qty 320 mg/ml) - injection, solution - excipient ingredients: trometamol; sodium calcium edetate; water for injections; trometamol hydrochloride; sodium hydroxide - this product accepted for registration as 'currently supplied' at the time of commencement of the act. indications approved as specified in the letter of 19 april 1993 from dr h. arora are as follows: optiray is indicated in adults for angiography throughout the cardiovascular system by conventional or digital subtraction techniques. these include cerebral, coronary, peripheral, visceral and renal arteriography, aortography, left ventriculography and venography. optiray may be used in intravenous excretory urography. optiray 320 is indicated in children (excluding neonates) for angiography, contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography.

Australia - English - Department of Health (Therapeutic Goods Administration)

guerbet australia pty ltd - ioversol, quantity: 678 mg/ml (equivalent: iodine, qty 320 mg/ml) - injection, solution - excipient ingredients: trometamol; sodium calcium edetate; water for injections; trometamol hydrochloride; sodium hydroxide - this product accepted for registration as 'currently supplied' at the time of commencement of the act. indications approved as specified in the letter of 19 april 1993 from dr h. arora are as follows: optiray is indicated in adults for angiography throughout the cardiovascular system by conventional or digital subtraction techniques. these include cerebral, coronary, peripheral, visceral and renal arteriography, aortography, left ventriculography and venography. optiray may be used in intravenous excretory urography. optiray 320 is indicated in children (excluding neonates) for angiography, contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography.

Australia - English - Department of Health (Therapeutic Goods Administration)

guerbet australia pty ltd - ioversol, quantity: 678 mg/ml (equivalent: iodine, qty 320 mg/ml) - injection, solution - excipient ingredients: trometamol; sodium calcium edetate; water for injections; trometamol hydrochloride; sodium hydroxide - this product accepted for registration as 'currently supplied' at the time of commencement of the act. indications approved as specified in the letter of 19 april 1993 from dr h. arora are as follows: optiray is indicated in adults for angiography throughout the cardiovascular system by conventional or digital subtraction techniques. these include cerebral, coronary, peripheral, visceral and renal arteriography, aortography, left ventriculography and venography. optiray may be used in intravenous excretory urography. optiray 320 is indicated in children (excluding neonates) for angiography, contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography.

Australia - English - Department of Health (Therapeutic Goods Administration)

guerbet australia pty ltd - ioversol, quantity: 678 mg/ml (equivalent: iodine, qty 320 mg/ml) - injection, solution - excipient ingredients: trometamol; sodium calcium edetate; water for injections; trometamol hydrochloride; sodium hydroxide - this product accepted for registration as 'currently supplied' at the time of commencement of the act. indications approved as specified in the letter of 19 april 1993 from dr h. arora are as follows: optiray is indicated in adults for angiography throughout the cardiovascular system by conventional or digital subtraction techniques. these include cerebral, coronary, peripheral, visceral and renal arteriography, aortography, left ventriculography and venography. optiray may be used in intravenous excretory urography. optiray 320 is indicated in children (excluding neonates) for angiography, contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - sodium amidotrizoate, quantity: 100 mg/ml; amidotrizoate meglumine, quantity: 660 mg/ml - injection, solution - excipient ingredients: water for injections; disodium edetate - intravenous and retrograde urography. computerised tomography. also for all angiographic examinations as well as for amniography, arthrography, intraoperative cholangiography, fistulography, hysterosalpingography, splenoportography, vesiculography and others. urografin is not to be used for myelography, ventriculography or cisternography since it is likely to provoke neurotoxic symptoms in the examinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

guerbet australia pty ltd - ioversol, quantity: 678 mg/ml (equivalent: iodine, qty 320 mg/ml) - injection, solution - excipient ingredients: trometamol; sodium calcium edetate; water for injections; trometamol hydrochloride; sodium hydroxide - this product accepted for registration as 'currently supplied' at the time of commencement of the act. indications approved as specified in the letter of 19 april 1993 from dr h. arora are as follows: optiray is indicated in adults for angiography throughout the cardiovascular system by conventional or digital subtraction techniques. these include cerebral, coronary, peripheral, visceral and renal arteriography, aortography, left ventriculography and venography. optiray may be used in intravenous excretory urography. optiray 320 is indicated in children (excluding neonates) for angiography, contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - morphine hydrochloride trihydrate, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections; dilute hydrochloric acid - - short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. - symptomatic relief of severe and intractable pains in terminal cancer patients. - use as a pre-operative medication and as an analgesic adjunct in general anaesthesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - morphine hydrochloride trihydrate, quantity: 10 mg/ml - injection, solution - excipient ingredients: dilute hydrochloric acid; water for injections - - short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. - symptomatic relief of severe and intractable pains in terminal cancer patients. - use as a pre-operative medication and as an analgesic adjunct in general anaesthesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - morphine hydrochloride trihydrate, quantity: 20 mg/ml - injection, solution - excipient ingredients: dilute hydrochloric acid; water for injections - - short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. - symptomatic relief of severe and intractable pains in terminal cancer patients. - use as a pre-operative medication and as an analgesic adjunct in general anaesthesia.